Linked Life Data

19824461

Source:http://linkedlifedata.com/resource/pubmed/id/19824461

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2009-10-14
pubmed:abstractText
Ovarian cancer treatment after cytoreductive surgery is based solely on chemotherapy. Pegylated liposomal doxorubicin (PLD) is a cytotoxic agent of verified efficacy in the treatment of ovarian cancer and is may be used in the first and the following lines of chemotherapy. In the first-line ovarian cancer treatment the combination of PLD with carboplatin assures a prolonged interval to progression and produces less toxicity when compared to carboplatin with paclitaxel schedule. Calypso trial has also revealed that in platinum-sensitive recurrent ovarian cancer PLD with carboplatin shows better anticancer efficiency in comparison to combination carboplatin with paclitaxel and its toxicity profile is quite unique. Namely PLD does not cause hematological complications, neuropathy balding and hair loss that are characteristic of other chemotherapeutics applied in ovarian cancer treatment. Palmar-plantar erythrodysesthesia, a typical and commonly noted adverse event, rarely occurs when the dosage is 40 mg/m2 iv. Thus, PLD ought to be the drug of choice in recurrent ovarian cancer treatment, both platinum-sensitive and platinum-insensitive one. In case of partially platinum-sensitive ovarian cancer PLD allows for a longer without-platinum period what in turn allows for yet another treatment with platinum, and helps achieve a prolonged interval to progression and progression-free survival time.
pubmed:language
pol
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0017-0011
pubmed:author
pubmed:issnType
Print
pubmed:volume
80
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
615-9
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Pegylated liposomal doxorubicin in ovarian cancer treatment].
pubmed:affiliation
Klinika Ginekologii Onkologicznej Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu. onko@gpsk.am.poznan.pl
pubmed:publicationType
Journal Article, English Abstract, Review